ALLMedicine™ Erythroleukemia Center
Research & Reviews 164 results
https://doi.org/10.2174/1874467215666220516143155
Current Molecular Pharmacology; Asgaritarghi G, Farsani SSM et. al.
May 18th, 2022 - Background Solanine was primarily known as a toxic compound. Nonetheless, recently the apoptotic role of solanine through suppression of PI3K/AKT/mTOR signaling pathway has been shown against many malignancies except chronic myelogenous leukemia (...
https://doi.org/10.1182/blood.2021014465
Blood Li B, An W et. al.
Apr 15th, 2022 - Leukemic transformation (LT) of myeloproliferative neoplasm (MPN) has a dismal prognosis and is largely fatal. Mutational inactivation of TP53 is the most common somatic event in LT; however, the mechanisms by which TP53 mutations promote LT remai...
https://doi.org/10.1080/09537104.2021.1988548
Platelets Hu L, Zhang W et. al.
Oct 27th, 2021 - Megakaryocytes (MKs) are the unique non-pathological cells that undergo polyploidization in mammals. The polyploid formation is critical for understanding the MK biology, and transcriptional regulation is involved in the differentiation and matura...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436216
Molecular Medicine Reports; Diab D, Pinon A et. al.
Aug 31st, 2021 - Natural agents have been used to restart the process of differentiation that is inhibited during leukemic transformation of hematopoietic stem or progenitor cells. Autophagy is a housekeeping pathway that maintains cell homeostasis against stress ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634195
Haematologica Cao JZ, Bigelow K et. al.
Aug 27th, 2021 - BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines.|2021|Cao JZ,Bigelow K,Wickrema A,Godley LA,|genetics,drug therapy,genetics,metabolism,
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT01143545
Mar 3rd, 2020 - Background: During recent years, the cancer-testis (CT) antigens have emerged as attractive targets for cancer immunotherapy. Whereas lung and esophageal cancers, as well as malignant pleural mesotheliomas express a variety of CT antigens, immune ...
https://clinicaltrials.gov/ct2/show/NCT01313429
Mar 3rd, 2020 - Background: During recent years, the cancer-testis (CT) antigens (CTA) have emerged as attractive targets for cancer immunotherapy. Whereas malignancies of diverse histologies express a variety of CTAs, immune responses to these antigens appear un...
News 2 results
https://www.onclive.com/view/understanding-the-recent-who-mds-classification-updates
Apr 2nd, 2021 - Transcript:Vinod Pullarkat, MD: Hello, and thank you for joining us today for this OncLive Peer Exchange® on the topic of Myelodysplastic Syndrome: Managing Risk and Complications. Myelodysplastic syndrome is a heterogeneous disease that necessita...
https://www.mdedge.com/hematology-oncology/article/185742/leukemia-myelodysplasia-transplantation/inhibitor-exhibits
HT Staff
Apr 18th, 2017 - Photo by Rhoda Baer Researchers in the lab A dual kinase inhibitor is active against a range of hematologic malignancies, according to preclinical research. Investigators found that ASN002, a SYK/JAK inhibitor, exhibited “potent” antiproliferative.